— Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on upadacitinib’s long-term economic value were split between “low” and “intermediate” due to concerns about the generalizability of the clinical data to patients in the real world — — During the policy roundtable, experts expressed frustration over the […]
— Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic and conservative benefit scenarios; new dimensions of benefits and contextual considerations for voting; and two new scenarios that display the potential impact on pricing that would result from sharing the savings of downstream cost offsets between society […]
— Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis on real-world evidence, revised approach to voting on contextual considerations, and a formal process for report updates at 12 months after initial release — — Proposals to be discussed during a webinar on September 4; Public comment […]
— NICE in the UK and CADTH in Canada among international agencies participating; Public input on key methodological issues is being accepted through February 20, 2019 — BOSTON, January 23, 2019 – The Institute for Clinical and Economic Review (ICER) today announced a new project to develop and test alternative methods for the evaluation of […]
— Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first encourage patients to try oral contraceptives and leuprorelin acetate before progressing to a new treatment that has an unknown long-term safety profile — Boston – August 3, 2018 – The Institute for Clinical and Economic Review today released […]
San Francisco, Calif., February 4, 2014 – The Institute for Clinical and Economic Review (ICER) today announced the new members of the 2014 California Technology Assessment Forum (CTAF). Fifteen California-based physicians, consumer representatives, and methodologists representing a wide variety of backgrounds, specialties, and perspectives comprise the newly re-constituted CTAF. CTAF Panel members have experience in […]